Glenmark anticipates innovative products will drive nearly seventy percent of its revenue
Glenmark expects innovative products, particularly in oncology, to generate nearly 70% of its revenue within 5-6 years, marking a significant shift from its traditional generics-led model. Chairman Glenn Saldanha details new drug applications and the role of AI in accelerating drug discovery.

















